Research
Hormonal
Evidence suggests a reduced incidence of several gastrointestinal cancers with GLP-1 receptor agonist use.
GLP-1 receptor agonists may be considered for patients at risk of gastrointestinal cancers.
StrongSupportsmedium confidence
Evidence suggests a reduced incidence of several gastrointestinal cancers.
Why this rating
Supported by a synthesis of evidence from clinical trials and studies.
Source
Review Article: The Evolving Role of <scp>GLP</scp> ‐1 Receptor Agonists in Gastroenterology Practice
Sydney Pomenti et al. · Alimentary Pharmacology & Therapeutics · 2025
DOI 10.1111/apt.70450
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →